This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
QIAGEN (QGEN)-Mirati Deal to Boost Companion Diagnostic Arm
by Zacks Equity Research
QIAGEN's (QGEN) alliance will facilitate co-development of KRAS companion diagnostic with Mirati's, adagrasib, a selective and potent oral inhibitor of KRAS G12C.
Exact Sciences (EXAS) Reveals Promising Data on Cologuard
by Zacks Equity Research
Modeling data exhibits efficacy of Exact Sciences' (EXAS) Cologuard compared to FIT and other colorectal cancer diagnostic options.
CVS Health (CVS) Launches Clinical Trial Services Business
by Zacks Equity Research
The latest clinical trial experience from CVS Health (CVS) is expected to overcome multiple challenges posed by its current clinical trial model.
Intersect ENT (XENT) Receives CE Mark for PROPEL Contour
by Zacks Equity Research
The CE Mark approval is backed by positive results from Intersect ENT's (XENT) PROGRESS clinical study of the PROPEL Contour.
Medtronic (MDT) Reveals Promising Results From Evolut Trial
by Zacks Equity Research
The Low Risk Trial has demonstrated non-inferiority of Medtronic's (MDT) TAVR system over open heart surgery.
PetIQ (PETQ) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
PetIQ (PETQ) delivered earnings and revenue surprises of 200.00% and 20.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: PetIQ (PETQ) Q1 Earnings Expected to Decline
by Zacks Equity Research
PetIQ (PETQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
PetIQ (PETQ) Surges 5.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
PetIQ (PETQ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
PetIQ (PETQ) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
PetIQ (PETQ) delivered earnings and revenue surprises of 16.67% and 12.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
PetIQ (PETQ) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
PetIQ (PETQ) delivered earnings and revenue surprises of -168.75% and -2.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Can PetIQ (PETQ) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
PetIQ (PETQ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
PetIQ (PETQ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
PetIQ (PETQ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo (PRGO) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Perrigo (PRGO) reports decent second-quarter 2020 results. The addition of products following Ranir acquisition boosts sales in the quarter.
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
Earnings Preview: PetIQ (PETQ) Q2 Earnings Expected to Decline
by Zacks Equity Research
PetIQ (PETQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PetIQ (PETQ) Catches Eye: Stock Jumps 8.4%
by Zacks Equity Research
PetIQ (PETQ) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Top Ranked Growth Stocks to Buy for May 7th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, May 7th
PETQ vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PETQ vs. BSX: Which Stock Is the Better Value Option?
Analysts Estimate PetIQ (PETQ) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
PetIQ (PETQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo (PRGO) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Perrigo (PRGO) reports decent first-quarter 2019 results. The addition of products following Ranir acquisition and stock piling due to COVID-19 boosts sales in the quarter.
Is a Beat in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
6 Valuable Price-to-Book Stocks to Buy as Recession Lurks
by Kinjel Shah
Though price-to-earnings and price-to-sales are the first choices, P/B ratio is also a convenient tool for identifying valuable stocks.